0
Skip to Content
Nordic Migraine Symposium 2026
Home
Agenda
Venue & Accommodation
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW
Nordic Migraine Symposium 2026
Home
Agenda
Venue & Accommodation
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW
Home
Agenda
Venue & Accommodation
Folder: Previous years
Back
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW

The gut microbiota and its influence on migraine

Session 1: Migraine pathophysiology

Filip Scheperjans

MD, Adjunct Professor of Neurology, Neurocenter, Helsinki University Hospital, Clinicum, Helsinki University, Finland

Download presentation

Previous

Migraine biomarkers in biofluids

Next

Should we treat during the prodromal phase? Pro

You Might Also Like

Related Embedded Video Item Thumbnail How to evaluate drug effectiveness in migraine?
Related Embedded Video Item Thumbnail Migraine preventative treatment recommendations/reimbursement conditions in the Nordics – What has changed in the last 5-6 years?
Related Embedded Video Item Thumbnail Switching between anti-CGRP monoclonal antibodies and gepants
Related Embedded Video Item Thumbnail Should we use combination therapy in migraine treatment? Pro
Related Embedded Video Item Thumbnail Should we treat during the prodromal phase? Con

Privacy policy

Teva Privacy Notice |Teva Pharmaceuticals

Legal Notes | Teva Pharmaceuticals

Accessibility Statement

Teva code of conduct


Norway, Finland, Denmark: AJO-DK-NP-00128